Sobi to Acquire CTI BioPharma In A Transaction Worth $1.7B
Author: Benzinga Newsdesk | May 10, 2023 03:31am
CTI BioPharma (NASDAQ:
CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has
CTI BioPharma (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB (STO: SOBI) ("Sobi"), a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion.
Posted In: CTIC